Solara Active Pharma Sciences Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32
SOLARA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Solara Active Pharma Sciences has filed its quarterly statement confirming there is no deviation or variation in the use of proceeds from its Rights Issue. Total funds raised stand at Rs. 308.85 Crores, of which Rs. 4.88 Crores was received this quarter from a 1st call reminder notice. For the originally stated object of repaying/pre-paying borrowings, Rs. 233.61 Crores has been utilised out of the Rs. 334.71 Crores allocation. For General Corporate Purposes, Rs. 74.97 Crores has been utilised out of a Rs. 112.24 Crores allocation, with Rs. 15.83 Crores deployed during the quarter, staying within the 25% cap on fresh issue proceeds. The Audit Committee reviewed the statement on November 5, 2025 and had no comments, while CRISIL Ratings Limited is acting as the monitoring agency.
Routine positive compliance filing — confirms the company is deploying Rights Issue funds as originally disclosed, with no misuse or change in stated purpose. No material price impact expected, but it reinforces capital allocation discipline for shareholders.